- Trials with a EudraCT protocol (94)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
94 result(s) found for: Non-alcoholic steatohepatitis.
Displaying page 1 of 5.
EudraCT Number: 2009-015166-62 | Sponsor Protocol Number: EME-08/43/15 | Start Date*: 2010-11-16 | |||||||||||
Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: A randomised controlled trial of Losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. | |||||||||||||
Medical condition: Fibrosis in patients with non-alcoholic steatohepatitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021515-17 | Sponsor Protocol Number: N/A | Start Date*: 2010-09-30 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: RiFL: Rifaxamin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)? | |||||||||||||
Medical condition: Non-alcoholic steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000685-39 | Sponsor Protocol Number: NN9931-4296 | Start Date*: 2016-10-13 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis. A 72-week randomised, double-blind, ... | |||||||||||||
Medical condition: Non-alcoholic steatohepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) GR (Completed) BG (Completed) FI (Completed) SE (Completed) NL (Completed) AT (Completed) BE (Completed) FR (Completed) ES (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003443-31 | Sponsor Protocol Number: NUT-3/NAS | Start Date*: 2019-06-10 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomised, placebo-controlled, phase IIb trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis (NASH) | |||||||||||||
Medical condition: Non-alcoholic steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (GB - no longer in EU/EEA) AT (Completed) HU (Completed) PL (Completed) ES (Ongoing) DE (Completed) LV (Completed) BE (Completed) GR (Prematurely Ended) NL (Completed) FR (Completed) DK (Completed) PT (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004373-50 | Sponsor Protocol Number: 369852 | Start Date*: 2021-04-08 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Effect of treatment with Semaglutide on cognitive function, neuroinflammation and hepatic nitrogen metabolism in patients with non-alcoholic steatohepatitis: A randomized placebo-controlled trial | |||||||||||||
Medical condition: Non-alcoholic steatohepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008275-34 | Sponsor Protocol Number: Edi-Omeg3-08001 | Start Date*: 2009-08-20 | |||||||||||
Sponsor Name:NHS Lothian [...] | |||||||||||||
Full Title: The Effect of Omega-3 Fatty Acids on Non-Alcoholic Fatty Liver Disease | |||||||||||||
Medical condition: Non-alcoholic fatty liver disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005089-12 | Sponsor Protocol Number: TRO19622 CL E Q 1159-1 | Start Date*: 2008-02-05 | |||||||||||
Sponsor Name:TROPHOS | |||||||||||||
Full Title: Study title: Double-blind vs Placebo, Randomized, Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 500 mg QD for One Month in Patients with Non-Alcoholi... | |||||||||||||
Medical condition: - Non Alcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003566-39 | Sponsor Protocol Number: NN9500-4656 | Start Date*: 2021-06-29 | |||||||||||
Sponsor Name:NOVO NORDISK. S.P.A. | |||||||||||||
Full Title: Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial | |||||||||||||
Medical condition: Non-alcoholic steatohepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001897-27 | Sponsor Protocol Number: GC41033 | Start Date*: 2020-01-07 | |||||||||||
Sponsor Name:Genentech Inc | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TOEVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF BFKB8488A COMPAREDWITH PLACEBO IN PATIENTS WITH ... | |||||||||||||
Medical condition: Non-alcoholic steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002325-37 | Sponsor Protocol Number: H80-MC-O008 | Start Date*: 2008-07-08 | |||||||||||
Sponsor Name:Department of Medicine I, University Hospital St. Josef-Hospital, Ruhr University Bochum | |||||||||||||
Full Title: Effects of Exenatide (Byetta®) on biochemical and histological parameters of liver function in patients with Nonalcoholic Steatohepatitis (NASH) – a randomized, placebo-controlled, parallel-group t... | |||||||||||||
Medical condition: Non alcoholic steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004594-44 | Sponsor Protocol Number: NN9931-4553 | Start Date*: 2021-06-28 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis | |||||||||||||
Medical condition: Non-alcoholic steatohepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) DE (Ongoing) IE (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005245-32 | Sponsor Protocol Number: CF102-212LD | Start Date*: 2023-05-09 | |||||||||||
Sponsor Name:CanFite BioPharma Ltd. | |||||||||||||
Full Title: A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) | |||||||||||||
Medical condition: Non-Alcoholic Steatohepatitis (NASH) and F1-3 fibrosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003012-61 | Sponsor Protocol Number: EFC10143 | Start Date*: 2008-02-01 | |||||||||||
Sponsor Name:sanofi recherche & developpement | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH) | |||||||||||||
Medical condition: Non diabetic patients with Non-Alcoholic Steato-Hepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) DE (Prematurely Ended) BE (Completed) ES (Completed) HU (Prematurely Ended) IT (Prematurely Ended) FR (Suspended by CA) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003013-14 | Sponsor Protocol Number: EFC10144 | Start Date*: 2008-02-01 | |||||||||||
Sponsor Name:sanofi-aventis recherche & development | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of Type 2 diabetic patients with nonalcoholic steatohepatitis (NASH) | |||||||||||||
Medical condition: Diabetic patients with Non-Alcoholic Steato-Hepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) BE (Completed) DE (Prematurely Ended) HU (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Suspended by CA) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003168-37 | Sponsor Protocol Number: CAIN457ADE15 | Start Date*: 2019-12-04 | ||||||||||||||||
Sponsor Name:Novartis Pharma GmbH | ||||||||||||||||||
Full Title: A randomized, double-blind, multicenter, 24-week study of subcutaneous secukinumab to assess anti-interleukin-17A treatment in plaque psoriasis patients with coexisting non-alcoholic fatty liver di... | ||||||||||||||||||
Medical condition: plaque psoriasis with coexisting non-alcoholic fatty liver disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001774-24 | Sponsor Protocol Number: 3574 | Start Date*: 2006-09-13 |
Sponsor Name:Newcastle u Tyne Hospitals NHS Trust | ||
Full Title: INTESTINAL MICRO-ORGANISMS IN THE PATHOGENESIS OF NASH AND THE ROLE OF MODULATION OF ENTERIC BACTERIA IN TREATMENT. | ||
Medical condition: Non alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2013-004605-38 | Sponsor Protocol Number: NUC-4/NAS | Start Date*: 2015-02-11 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of non-alcoholic fatty liver di... | |||||||||||||
Medical condition: Non-alcoholic fatty liver disease (NAFLD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005531-28 | Sponsor Protocol Number: Urso in Obese | Start Date*: 2008-04-03 | |||||||||||
Sponsor Name:Hanns-Ulrich Marschall | |||||||||||||
Full Title: Ursodeoxycholic Acid in Morbidly Obese Patients Before Bariatric Surgery | |||||||||||||
Medical condition: Patients with morbid obesity (MB) are investigated. MB is very frequently (90%) associated with non-alcoholic fatty liver disease (NAFLD) comprising a spectrum reaching from steatosis (NAFL) over s... | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002114-19 | Sponsor Protocol Number: 9831-CL-0301 | Start Date*: 2008-02-27 | |||||||||||
Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
Full Title: A phase II, randomized, double-blind, parallel-group, placebo-controlled, 12-week treatment, adaptive proof-of-principle study of twice daily oral dosing of a novel PDE4 inhibitor (ASP9831) in subj... | |||||||||||||
Medical condition: Non-alcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) CZ (Completed) FR (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003164-21 | Sponsor Protocol Number: 652-2-203 | Start Date*: 2015-01-05 | |||||||||||
Sponsor Name:Tobira Therapeutics, Inc., a subsidiary of Allergan plc | |||||||||||||
Full Title: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis | |||||||||||||
Medical condition: Nonalcoholic Steatohepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
